The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). Wh

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.45) per share which beat the analys

Truist Securities analyst Danielle Brill maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and

JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ:MAZE) with a Overweight and rai

The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp

US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur

BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains

Maze Therapeutics stock drops despite Phase 2 data showing uACR reductions in APOL1 kidney disease;

HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy

 – At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients,

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.65) per share which beat the analys

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S

Truist Securities analyst Danielle Brill initiates coverage on Maze Therapeutics (NASDAQ:MAZE) wi

Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raise

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1

Mizuho analyst Salim Syed initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Outperform

BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains

Guggenheim analyst Debjit Chattopadhyay maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and

BTIG analyst Julian Harrison maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the